343305-12-4

Basic information

• Product Name: methyl 3-(3-methoxyphenyl)-2-methyl-3-oxopropanoate
• Synonyms: methyl 3-(3-methoxyphenyl)-2-methyl-3-oxopropanoate
• CAS NO: 343305-12-4
• Molecular Weight: 222.241
• Mol File: 343305-12-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: methyl 3-(3-methoxyphenyl)-2-methyl-3-oxopropanoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3-(3-methoxyphenyl)-2-methyl-3-oxopropanoate(343305-12-4)
• EPA Substance Registry System: methyl 3-(3-methoxyphenyl)-2-methyl-3-oxopropanoate(343305-12-4)

Safety Data

• Hazardous Substances Data: 343305-12-4(Hazardous Substances Data)

Upstream product

• 554-12-1 propanoic acid methyl ester 
• 5368-81-0 methyl 3-methoxybenzoate 
• 586-38-9 3-Methoxybenzoic acid 
• 152121-82-9 N,3‐dimethoxy‐N‐methylbenzamide 
• 37951-49-8 1-(3-methoxyphenyl)propan-1-one 
• 616-38-6 carbonic acid dimethyl ester 
• 19438-10-9 methyl 3-hydroxybenzoate 

Downstream Products

• 343305-14-6 5-(3-methoxyphenyl)-4-methyl-3-isoxazolol 
• 1010800-74-4 3-(3-hydroxyphenyl)-4,4-dimethyl-1H-pyrazol-5(4H)-one 
• 1010800-73-3 3-(3-methoxyphenyl)-4,4-dimethyl-1H-pyrazol-5(4H)-one 
• 1010801-86-1 C₂₉H₃₁F₃N₆O₄ 
• 343305-23-7 methyl 2-acetylamino-3-[3-pivaloyloxy-5-(3-methoxyphenyl)-4-isoxazolyl]-2-(methoxycarbonyl)propionate 
• 343305-20-4 4-bromomethyl-3-pivaloyloxy-5-(3-methoxyphenyl)isoxazole 
• 343305-17-9 3-pivaloyloxy-5-(3-methoxyphenyl)-4-methyl-isoxazole 

Relevant articles and documents

Phosphodiesterase inhibitors. Part 5: Hybrid PDE3/4 inhibitors as dual bronchorelaxant/anti-inflammatory agents for inhaled administration

(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl) -5-methyl-4,5-dihydropyridazin-3(2H)-one (KCA-1490) exhibits moderate dual PDE3/4-inhibitory activity and promises as a combined bronchodilatory/anti- inflammatory agent. N-alkylation of the pyridazinone ring markedly enhances potency against PDE4 but suppresses PDE3 inhibition. Addition of a 6-aryl-4,5-dihydropyridazin-3(2H)-one extension to the N-alkyl group facilitates both enhancement of PDE4-inhibitory activity and restoration of potent PDE3 inhibition. Both dihydropyridazinone rings, in the core and extension, can be replaced by achiral 4,4-dimethylpyrazolone subunits and the core pyrazolopyridine by isosteric bicyclic heteroaromatics. In combination, these modifications afford potent dual PDE3/4 inhibitors that suppress histamine-induced bronchoconstriction in vivo and exhibit promising anti-inflammatory activity via intratracheal administration.

PYRAZOLONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT

It is to provide a novel pyrazolone derivative represented by the following general formula (1), which is useful as a pharmaceutical and has a phosphodiesterase inhibitory action: wherein R1,R2: C1-6 alkyl; R3,R4: H, X, C1-6 alkoxy; Z:O, S; A:AA, BB, wherein AA represents wherein BB represents wherein R5: H, C1-6 alkyl ; R6,R7: C1-6 alkyl.